Premixed insulin
Premixed insulin
INS_PREMIX
Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.
Related
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.76 (-1.17 to -0.32) | 0.39 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.73 (-1.15 to -0.28) | 0.40 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD 0.71 (0.13 to 1.34) | 0.08 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD 0.12 (-1.31 to 1.59) | 0.31 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Standard care or no added treatment | MD 0.20 (-1.15 to 1.37) | 0.33 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Standard care or no added treatment | MD 0.20 (-1.16 to 1.36) | 0.34 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Insulin degludec and liraglutide (IDegLira) subcutaneous once daily titrated | MD 0.30 (-0.58 to 1.10) | 0.48 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Insulin degludec with liraglutide injection | MD 0.30 (-0.56 to 1.11) | 0.49 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Exenatide 10 ug subcutaneous twice daily | MD 4.79 (1.24 to 7.65) | 0.01 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD 1.18 (-6.29 to 9.59) | 0.33 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 2.63 (0.76 to 4.21) | 0.12 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 2.47 (0.23 to 4.55) | 0.19 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Insulin degludec and liraglutide (IDegLira) subcutaneous once daily titrated | MD 5.32 (1.46 to 9.90) | 0.07 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Insulin degludec with liraglutide injection | MD 5.38 (1.70 to 9.74) | 0.06 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.12 (0.00 to 4.00) | 0.67 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.10 (0.00 to 3.66) | 0.66 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 16.07 (3.06 to 89.09) | 0.07 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 12.19 (2.63 to 61.77) | 0.08 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.10 (0.98 to 4.75) | 0.34 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.04 (0.87 to 4.99) | 0.37 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 5.21 (1.52 to 17.56) | 0.12 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 4.86 (1.12 to 18.58) | 0.13 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -0.79 (-6.58 to 4.94) | 0.37 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -0.75 (-6.95 to 5.26) | 0.42 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 4.06 (-1.46 to 10.02) | 0.38 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 1.04 (-4.24 to 8.51) | 0.42 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.67 (0.41 to 1.07) | 0.69 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.65 (0.39 to 1.05) | 0.79 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.18 (0.02 to 0.95) | 0.91 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.18 (0.02 to 0.96) | 0.91 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.16 (0.08 to 0.31) | 0.95 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.17 (0.08 to 0.36) | 0.90 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.42 (0.19 to 0.87) | 0.88 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.45 (0.18 to 1.00) | 0.83 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.47 (0.26 to 0.85) | 0.90 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.49 (0.26 to 0.90) | 0.88 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.07 (0.00 to 0.73) | 0.95 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.08 (0.00 to 0.82) | 0.93 |
Trials
- S002992887 randomized · 26 weeks
- S0030042020 · 134 randomized · 26.07 weeks
- S0030442015 · 95 randomized · 24 weeks
- NCT02449603Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes : a Randomised Open Parallel-controlled Study2015 · 104 randomized · 16 weeks
- S0030302015 · 66 randomized · 52 weeks
- NCT01147627Comparison of Exenatide, Insulin or Pioglitazone on Glycaemic Control and β-cell Function in Drug-naïve Type 2 Diabetic Patients: A Multicentre Randomized Parallel-group Trial2010 · 416 randomized · 48 weeks
- NCT00434954Effect of Exenatide Plus Metformin vs. Premixed Human Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Inadequate Control of Type 2 Diabetes on Oral Antidiabetic Treatment2007 · 494 randomized · 26 weeks
- NCT00082407Efficacy of Exenatide (AC2993, Synthetic Exendin-4, LY2148568) Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin2003 · 505 randomized · 52 weeks